You just read:

PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)

News provided by

PDL BioPharma, Inc.

May 24, 2016, 16:02 ET